Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: DiaGenic Names de Potocki as CEO

Premium

DiaGenic has named Paul de Potocki as president and CEO, effective in September.

De Potocki will succeed Henrik Lund, who had been DiaGenic's interim CEO since April. He most recently served as CEO of Aerocrine. He has also served as senior vice president of commercial and strategic development at Biovitrium; and executive vice president of strategic marketing at Fresenius Kabi.

Oslo-based DiaGenic has developed technology to identify gene expression signatures in peripheral blood and the company is focused on developing biomarkers in the field of Alzheimer’s and Parkinson’s diseases. DiaGenic’s Alzheimer’s disease development program includes the CE-marked diagnostic test ADtect for detection of mild to moderate Alzheimer’s disease, and MCItect, which is under development for identifying patients with very early stages of Alzheimer’s disease.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.